Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics, Origins, and Biosignature Preservation Potential of Carbonate-Bearing Rocks Within and Outside of Jezero Crater.

Journal of geophysical research. Planets·2021
Same author

Earth-like Habitable Environments in the Subsurface of Mars.

Astrobiology·2021
Same author

Changes in Phosphoinositides in Rabbit Platelets during Clot Formation. Comparison of Platelets Stimulated by ADP or by Thrombin in the Presence of Polymerising Fibrin.

Platelets·2010
Same author

Ontario's Mustard Report: Its Implications For Family Physicians.

Canadian family physician Medecin de famille canadien·2010
Same author

Closing remarks / conclusion.

Canadian Medical Association journal·2010
Same author

Acute Myocardial Infarction in the Presence of Thrombocytopenia.

Canadian Medical Association journal·2010
Same journal

Dupilumab Emerges as an Effective Antibody Therapy for Eosinophilic Esophagitis.

Annual review of medicine·2026
Same journal

CAR T Cell Toxicities and Emerging Treatment Strategies.

Annual review of medicine·2026
Same journal

Transthyretin Amyloid Cardiomyopathy: A Rapidly Evolving Landscape.

Annual review of medicine·2026
Same journal

Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions.

Annual review of medicine·2026
Same journal

Diffuse Parenchymal Lung Disease: Updates in Pathophysiology and Management.

Annual review of medicine·2026
Same journal

Revascularization for Ischemic Cardiomyopathy: Disproving the 45-Year-Old Concept of Hibernating Myocardium.

Annual review of medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

Prostaglandins and platelets

J F Mustard, R L Kinlough-Rathbone, M A Packham

    Annual Review of Medicine
    |January 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Inhibiting phospholipase A1 is crucial for prostaglandin and thromboxane synthesis. However, clinical trials show cyclo-oxygenase inhibitors have limited impact on arterial thromboembolic disease.

    More Related Videos

    Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
    08:04

    Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

    Published on: June 10, 2025

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
    04:37

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

    Published on: May 23, 2025

    Related Experiment Videos

    Last Updated: Jun 23, 2026

    Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
    11:42

    Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

    Published on: July 10, 2017

    Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
    08:04

    Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

    Published on: June 10, 2025

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
    04:37

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

    Published on: May 23, 2025

    Area of Science:

    • Biochemistry
    • Pharmacology
    • Cardiovascular Research

    Background:

    • Phospholipase A1 activation releases arachidonate, a precursor for prostaglandins and thromboxanes.
    • Prostaglandins and thromboxanes play key roles in platelet aggregation and vascular function.
    • Inhibiting these pathways is a therapeutic target for modifying thrombus formation.

    Purpose of the Study:

    • To investigate the role of phospholipase A1 in arachidonate release and subsequent eicosanoid formation.
    • To evaluate the potential of enzyme inhibitors in managing thromboembolic complications.
    • To assess the clinical efficacy of cyclo-oxygenase inhibitors in arterial disease.

    Main Methods:

    • Enzyme assays to measure phospholipase A1 activity.
    • Analysis of prostaglandin and thromboxane synthesis.
    • Review of clinical trial data for cyclo-oxygenase inhibitors.

    Main Results:

    • Arachidonate release via phospholipase A1 is a critical initial step.
    • Platelet activation leads to thromboxane A2 (TXA2) formation, promoting aggregation.
    • Vascular tissue produces prostacyclin (PGI2), which inhibits platelet activity.
    • Clinical trials indicate limited benefits of cyclo-oxygenase inhibitors for arterial thromboembolic issues.

    Conclusions:

    • While phospholipase A1 is key, targeting cyclo-oxygenase may not be sufficient for treating arterial thromboembolic disease.
    • Further research into alternative targets for antithrombotic therapy is warranted.